Vicarious Surgical (RBOT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $13.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Josh Jennings has given his Buy rating due to a combination of factors that highlight Vicarious Surgical’s promising advancements and strategic planning. The company is on the cusp of reaching significant milestones, including the submission of a technical dossier by mid-2025, which is crucial for initiating first clinical treatments. This progress is expected to enhance investor confidence and strengthen the company’s financial position.
Furthermore, Vicarious Surgical has shown commendable progress in overcoming previous supply constraints, maintaining its development and clinical timelines without any delays. The successful construction of key components for preclinical testing, such as the patient cart and surgeon console, underscores the company’s preparedness for upcoming trials. These developments, coupled with the management’s confidence in meeting regulatory requirements, form the basis for Jennings’s optimistic outlook on the stock.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RBOT in relation to earlier this year.